男性荷爾蒙去除治療對於攝護腺癌病人下泌尿道症狀的影響—臺北榮總經驗

陳鵬1、黃逸修1,2、張延驊1,2、鍾孝仁1,2、黃子豪1,2、陳威任1,2、林志杰1,2、郭俊逸1,2

黃奕燊1,2、魏子鈞1,2、林登龍1,2、林子平1,2、范玉華1,2、黃志賢1,2

1臺北榮民總醫院 泌尿部;

2國立陽明交通大學醫學院泌尿學科 書田泌尿科學研究中心

The impact of androgen deprivation therapy on lower urinary tract symptoms in prostate cancer patients - a single institute experience

Peng Chen1, Eric Yi-Hsiu Huang1,2, Yen-Hwa Chang1,2, Hsiao-Jen Chung1,2, Tzu-Hao Huang1,2,

Wei-Ren Chen1,2, Chi-Cheh Lin1,2, Junne-Yih Kuo1,2, I-shen Huang1,2, Tzu-Chun Wei1,2, Alex T.L. Lin1,2, Tzu-Ping Lin1,2, Yu-Hua Fan1,2, William J. Huang1,2

1 Department of Urology, Taipei Veterans General Hospital;

2 Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

 

Purpose

Androgen deprivation therapy (ADT) has been well recognized as the cornerstone therapy for prostate cancer (PCa) patients across all risk groups. The lower urinary tract symptoms (LUTS) of advanced PCa patients may be contributed by both benign prostatic hyperplasia and the tumor. Therefore, ADT will impact the LUTS in patients with PCa. Moreover, some patients with advanced disease may accept concurrent ADT and radiation therapy (RT) which will probably further influence the LUTS. Hence, we aimed to analyze the effects of ADT on LUTS in patients with advanced PCa.

Materials and Methods

Patients diagnosed with PCa using ADT were enrolled prospectively. Those who received any prostate or urethra related surgery (transurethral resection of the prostate, radical prostatectomy, urethrotomy), bladder or urethra botulinum toxin injection, using 5-alpha reductase inhibitor and under Foley insertion were excluded. Patients with locally advanced PCa managed with concurrent ADT and RT were also enrolled. PSA and IPSS questionnaire were measured every 3 months. Transabdominal ultrasound and uroflowmetry (UFR) was performed at initial survey, 6-month, and 12-month follow up. Both descriptive and comparative statistical analyses were performed. The functional parameters between ADT alone and concurrent ADT+RT were compared using a repeated measures analysis of covariance (ANCOVA) model.

Results

45 patients were included with the mean age of 73.1±9.7 years. Twenty-one (46.7%) of them were metastatic disease, 21 (46.7%) were locally advanced, and 3 (6.6%) were localized disease. Seventeen patients (37.8%) were managed with concurrent ADT and RT. For the whole group, initial prostate volume was 55.27±31.55ml, IPSS was 14.31±7.56, maximal uroflow rate was 9.82±4.29 ml/sec, and mean uroflow rate was 4.64±2.53 ml/sec. At 3-month follow up, IPSS was 11.56±6.79 which was significantly lower than initial IPSS. At 6-month follow up, prostate volume, IPSS, and uroflow rate were also significantly improved than initial parameters. However, there were no significant differences for IPSS and uroflow rate at 9-month and 12-month follow up. In addition, there were no significant differences between patients who receiving ADT alone and ADT+RT in terms of IPSS, prostate volume, uroflow rate during follow up.

Conclusions

For PCa patients, ADT ameliorate LUTS significantly in both subjective and objective outcomes especially in the first 6 months. RT add on to ADT seemed not to influence the LUTS compared to those who accepted ADT alone.

    位置
    資料夾名稱
    摘要
    發表人
    TUA人資客服組
    單位
    台灣泌尿科醫學會
    建立
    2021-05-24 11:53:54
    最近修訂
    2021-05-24 11:54:44
    更多